TERMINATION AND TRANSFER AGREEMENTTermination and Transfer Agreement • April 11th, 2023 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances)
This TERMINATION AND TRANSFER AGREEMENT (this “Agreement”) is entered into as of April 6, 2023 (the “Effective Date”), by and between Adaptimmune Limited (registered number 6456207) whose registered office is at 60 Jubilee Avenue, Milton Park, Abingdon, Oxon, OX14 4RX, United Kingdom (“Adaptimmune”), and GlaxoSmithKline Intellectual Property Development Limited whose registered office is at 980 Great West Road, Middlesex, TW8 9GS, United Kingdom (“GSK”). Each of Adaptimmune and GSK are sometimes referred to herein individually as a “Party” and together as the “Parties.”
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune - Adaptimmune plans to be IND-ready in 2023 with a PRAME targeted TCR T-cell therapy - - Adaptimmune and GSK will work collaboratively to ensure...Transition Agreement • April 11th, 2023 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances)
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. – April 11, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in T-cell therapy to treat cancer, today announced entry into a transition agreement with GSK plc (LSE:GSK) (NYSE:GSK) regarding the return of rights and materials comprised within the PRAME and NY-ESO cell therapy programs.
